Monica Weldon Consulting, LLC

Call Directions Website Contact the business

Monica Weldon Consulting, LLC VA Gov Youngkin Appointee (CHRB)| Biotech | Applied Legal Analyst | Sr. We then began a journey to find answers to help our son.

Advisor | Strategist | Systems Thinker | Life Science Consultant | DOW | CBRN-WMD | National Defense | Cleared Secret | Legi Policy Advisor | Supply Chain Guru | SME | KOL | Speaker🎤 In November of 2012, Monica's twin son, Beckett, was the first to be diagnosed at Texas Children's Genetics Clinic with the gene mutation SYNGAP1. When Beckett was 4 months old, we noticed he was not meeting the same milestones as his twin sister. She began to blog about his progress & this led to building a community of parents & caregivers & a strong support group. She is the Founder, President/CEO of SYNGAP1 Foundation. SYNGAP1 is the top single gene mutation linked to Autism in the world and linked to many other neurological conditions, such as Intellectual Disability, Epilepsy, and Schizophrenia.
She retired in 2016 after 23 years in education teaching secondary science. Her new focus is on building the programs & mission of the Foundation. She is the Primary Investigator on the SYNGAP1 (MRD5) Registry & Natural History Study, the largest in the world. She is a life member of the Worldwide Association of Female Professionals, DIA 2016 Patient Scholar, a member of the first-class of 2017 Illumina Ambassadors established in the United States, and a member of Women in Bio – Capital DC and Texas Chapters. She was named “Top 10 Women Influential Leaders of 2022” by Era Industry Magazine.
In addition to leading the foundation, she is an author, public speaker, consultant on rare disease business strategies & advocates for rare disease legislation at both the federal & state levels. Several of her authored scientific publications include Nature Neuroscience, The Journal of Neurodevelopmental Disorders, The Journal of Pediatrics, and Value in Health Journal. She has written a book about her son. She attended Northwestern University Pritzker Law School, earning a Master in Science Law with a concentration in healthcare policy and health regulation, and is an applied legal professional.

The videos are now available! 🎥You can now watch the recorded testimony and public comments from the October 28, 2026, F...
11/06/2026

The videos are now available! 🎥

You can now watch the recorded testimony and public comments from the October 28, 2026, FDA Rare Disease Framework Initiative public meeting.

I had the privilege of participating in this historic conversation and providing public comment on the need to rethink how we approach rare disease drug development.

For patients and families living with rare diseases, this initiative represents an important opportunity to address the realities of developing treatments for small patient populations, where traditional regulatory expectations may not always reflect the evidence that can realistically be generated.

The FDA, in partnership with the Reagan-Udall Foundation for the FDA, is seeking public input on several critical areas:

* Fit-for-purpose evidence: Evaluating therapies based on the specific disease, disease state, patient population, and attainable evidence.
* Regulatory consistency: Improving predictability and consistency in FDA drug development and review requirements.
* Patient and expert engagement: Ensuring patients, disease experts, and researchers have a meaningful voice in regulatory decision-making.
* Chemistry, Manufacturing & Controls (CMC): Addressing the unique manufacturing and development challenges associated with rare disease therapies.

This conversation cannot end with a public meeting. It needs to translate into meaningful regulatory reform and, ultimately, better pathways to treatments for patients who cannot afford to wait.

If you are part of the rare disease community, a researcher, clinician, advocate, or industry stakeholder, I encourage you to watch the testimony and make your voice heard.

There is still an opportunity to submit written public comments.

📅 Deadline: December 11, 2026

📌 FDA Docket: FDA-2026-N-12214

Submit comments electronically through Regulations.gov or by written submission.

Our voices matter. The science matters. And the patients waiting for treatments matter most.



https://reaganudall.org/news-and-events/events/rare-disease-framework-public-meeting?eType=EmailBlastContent&eId=be0fc3c4-189f-4698-92a0-973c2b95f409

Reagan-Udall Foundation for the FDA, independent 501(c)(3) organization created by Congress to advance the mission of the Food and Drug Administration.

11/01/2026

🇺🇸 Excited to share a new chapter in my professional journey!

After a long road to get here, I am thrilled to share that I have officially started a new contract role supporting our nation’s Nuclear, Chemical, and Biological Defense mission.

This opportunity has been a long time coming, and I could not be more excited to be part of a team working on such a critical national security priority.

I am proud to bring my background in science, research, policy, and strategic planning to a mission focused on protecting our citizens and strengthening our nation’s defense capabilities. I look forward to contributing to the policy development, funding strategies, and strategic alignment needed to advance this important work.

Sometimes the road takes longer than we expect, but perseverance matters. I am incredibly grateful for the people who helped make this opportunity possible and excited about what lies ahead.

Proud to serve our nation. Grateful for the opportunity. Focused on the mission. 🇺🇸

10/29/2026

Today, I had the privilege of presenting oral public comment IN PERSON at the FDA’s Rare Disease Framework Initiative public meeting. Thank you to the FDA for the invitation and for making space for the voices of patients, families, and advocates.

A special thank-you to Acting FDA Commissioner Kyle Diamantas, Amy Comstock Rick, Mike Davis, Karim Mikhail, and everyone who stayed to listen and hear me out. I genuinely appreciate your time and willingness to engage with the rare disease community.

After time away from the rare disease policy arena, it felt GOOD to be back in the game—bringing years of research, advocacy, and lived experience as a rare disease mom back to the table.

Our families cannot afford to wait forever. We need regulatory approaches that recognize the realities of small patient populations, advance sound science, and create meaningful pathways toward treatments.

I’m grateful for the opportunity to contribute. We’ll see where things go from here, but today felt like a step in the right direction.

Sometimes God brings you full circle for a reason. 🙏🏻💜

I had the honor of judging and reviewing proposals in the Future of Health Innovation Tournament Challenge (FHITC) from ...
10/24/2026

I had the honor of judging and reviewing proposals in the Future of Health Innovation Tournament Challenge (FHITC) from the Center for Advancing Innovation, and I'm proud to share the results.

Congratulations to TIMSER, led by Mercedes Gutiérrez Smith, named CAI's first-ever Grand Champion following the inaugural Air Show. More than 30 investor judges evaluated the companies, and TIMSER earned the top overall ranking.

Congratulations also to all 16 participating companies, each now an FHITC TOPGUN Finalist. Together, participating companies raised or secured commitments totaling nearly $18 million, and the tournament has launched 16+ companies.

Advocates play an important role in helping entrepreneurs strengthen their businesses, connect with stakeholders, and prepare for investment. I look forward to continuing that work with this cohort and future participants.

FHITC remains open for rolling enrollment, with additional Grand Champions to be crowned in future rounds. Referrals are welcome for companies applying AI, high-performance computing, or quantum computing to advance human health or performance.

Read more:
Official press release: https://www.issuewire.com/through-the-future-of-health-innovation-tournament-challenge-cai-crowns-timser-its-first-ever-grand-champion-1879492091541979

Keep climbing!

10/24/2026

I was selected to give an in-person oral comment at FDA's Rare Disease Framework Initiative public meeting, Wednesday, October 28, 2:00 PM ET.

For two and a half years I've worked in national defense, helping government and industry build and navigate pathways to work together, including inside government helping change how it does business. Rare disease faces the same problem: the target keeps moving.

I helped draft the Promising Pathway Act 2.0, introduced in 2024. My recommendations build on its core ideas: real-world data, lowering the risk of trial failure, and giving payers evidence to cover conditionally approved therapies.

What I'll ask FDA to pilot:

1. Design trials with existing data: patient-focused drug development reports into endpoints, in one registry that serves as natural history, external control, and confirmation.

2. Build the Promising Pathway into FDA's rules.

3. Review past rare disease trials for missed endpoints and missing evidence, then publish a minimum evidence package by disease class.

4. Convene an industry consortium for small rare disease sponsors, as defense does, with independence rules, fair data terms, and firewalls, and teach patient communities to build data packages.

Each is a pilot: 2-3 rare diseases, 24 months, published measures. Safety and efficacy stay non-negotiable.

Comment too, Oct 28 to Dec 11 (docket FDA-2026-N-12214): https://lnkd.in/eqr-vTbg

Meeting details: https://lnkd.in/eeDVdib2


Secretary Kennedy U.S. Department of Health and Human Services (HHS) Kyle Diamantas Amy Comstock Rick Mike Davis Karim Mikhail, BPharm. MSc. Reagan-Udall Foundation for the FDA

Rare disease advocates need to start paying attention to critical minerals.The new report, Bringing Rare Disease Treatme...
10/07/2026

Rare disease advocates need to start paying attention to critical minerals.

The new report, Bringing Rare Disease Treatments to Patients, highlights a critical problem: developing a therapy is only part of the equation. We also need the manufacturing capacity and supply chains to actually produce it. Read the report at National Security Commission on Emerging Biotechnology (NSCEB)https://www.biotech.senate.gov/wp-content/uploads/2026/07/Rare-Disease-Vertical.pdf

That means we need to be talking about APIs, chemical precursors, critical minerals, advanced manufacturing and domestic production capacity.

These aren’t separate issues.

If we want to develop and manufacture therapies for rare diseases, we need a resilient supply chain behind those therapies. And that same biomanufacturing infrastructure is essential to national security, medical countermeasures and medicines for the warfighter.

For years, the rare-disease community has rightly focused on research funding, clinical trials, FDA pathways and access.

It’s time to move further upstream.

A therapy in a laboratory isn’t a treatment. A therapy we cannot reliably manufacture isn’t a treatment either.

Rare disease policy needs to be part of the conversation around critical minerals, API independence, biomanufacturing and national security.

The molecule-to-medicine pipeline is also part of America’s health-security pipeline.

10/02/2026

Excited to be back! 🇺🇸

After a year-long sabbatical, I’m heading to the Association of the United States Army - AUSA Annual Meeting & Exposition in Washington, D.C. — and I couldn’t be more excited to reconnect with the defense and national security community.

AUSA is one of the premier gatherings for the U.S. Army and broader defense ecosystem, bringing together military leaders, industry, policymakers, innovators, and national security professionals from around the world.

For me, this is more than an event. It’s a homecoming of sorts.

I’m looking forward to catching up with old colleagues, meeting new ones, talking strategy, innovation, policy, technology, and — most importantly — getting back to the work I love.

To all my national defense and national security colleagues — hit me up! I’m excited to see everybody again, reconnect, and meet the next generation of people shaping our national security future.

After a year away, I’m ready to get back to the grind.

More to come. 🇺🇸

Two years ago, I contributed to this report while serving as president of the SYNGAP1 Foundation. Looking back at it tod...
09/29/2026

Two years ago, I contributed to this report while serving as president of the SYNGAP1 Foundation. Looking back at it today, I see the issues through a very different lens.

Over the past decade, I’ve watched rare disease nonprofits—and even large umbrella organizations—build incredible programs, only to eventually run out of money, people, or both.

The problem isn’t a lack of passion or good ideas.

It’s sustainability.

We cannot continue building the future of healthcare and rare disease research on grants, donations, and the assumption that government will always have the resources to fill the gaps.

What if we started thinking differently?

What if we developed capitalistic models for public benefit—creating ways for organizations to generate sustainable value and reinvest a portion of that value back into the patients, research, and communities they serve?

This report is still relevant two years later. But I think it also points us toward a much bigger conversation about how we capitalize the healthcare and rare disease ecosystem so good work can actually survive.

I’d love to hear from others thinking about this.

Read the report here:
The Power of Patient Organizations in Advancing Health Equity⁠
DKI Health

https://www.dkihealth.com/thought-leadership/the-power-of-patient-organizations-in-advancing-health-equity?

DKI Health launched a first-of-its-kind study to measure how patient organizations think about health equity, where they have had successes, and which barriers still exist.

Address

Washington D.C., DC
20005

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+12029910203

Alerts

Be the first to know and let us send you an email when Monica Weldon Consulting, LLC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Monica Weldon Consulting, LLC:

Shortcuts

Share

Nearby businesses